Autoimmunizing mechanisms in thymoma and thymus - PubMed (original) (raw)
Autoimmunizing mechanisms in thymoma and thymus
Nick Willcox et al. Ann N Y Acad Sci. 2008.
Abstract
Autoimmunizing mechanisms are very hard to study in humans, so we have focused on vital clues in thymomas and hyperplastic thymuses in myasthenia gravis (MG). According to our multi-step hypothesis: thymic epithelial cells (TEC) present epitopes from the isolated acetylcholine receptor (AChR) subunits they express, and autoimmunize helper T cells; subsequently, these evoke "early antibodies" that then attack rare thymic myoid cells expressing intact AChR; in the resulting germinal centers, autoantibodies diversify to recognize native AChR. We have studied: 1) thymomas, to identify autoimmunizing cell types, focusing on IFN-alpha, against which many patients have high titer autoantibodies, as in another highly informative autoimmune syndrome. Although IFN-alpha is much easier to label than the sparse and delicate AChR subunits, we have not yet located obviously autoimmunizing micro-environments; 2) hyperplastic MG thymuses, where we find (a) upregulation of complement receptors and regulators on hyperplastic TEC and deposition of activated C3b complement component on them, (b) absence of complement regulators from almost all myoid cells, indicating vulnerability to attack, and (c) deposition of C3b, and even of the terminal membrane attack complex, especially on the myoid cells close to the infiltrating germinal centers. The changes are very similar in over 50% of the so-called seronegative patients with generalized MG (SNMG) but without detectable autoantibodies against AChR or MuSK, consistently with other evidence that they belong to the spectrum of AChR-seropositive MG. Together, moreover, our findings implicate both myoid cells and TEC in autoimmunization, and thus strongly support our hypothesis.
Similar articles
- A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.
Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, Pantic N, Newsom-Davis J, Vincent A, Willcox N. Nagvekar N, et al. J Clin Invest. 1998 May 15;101(10):2268-77. doi: 10.1172/JCI2068. J Clin Invest. 1998. PMID: 9593783 Free PMC article. - Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor.
Shiono H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, Meager A, Beeson D, Vincent A, Willcox N. Shiono H, et al. Int Immunol. 2003 Aug;15(8):903-13. doi: 10.1093/intimm/dxg088. Int Immunol. 2003. PMID: 12882828 - Scenarios for autoimmunization of T and B cells in myasthenia gravis.
Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N. Shiono H, et al. Ann N Y Acad Sci. 2003 Sep;998:237-56. doi: 10.1196/annals.1254.026. Ann N Y Acad Sci. 2003. PMID: 14592881 - Myasthenia gravis.
Marx A, Schultz A, Wilisch A, Nenninger R, Müller-Hermelink HK. Marx A, et al. Verh Dtsch Ges Pathol. 1996;80:116-26. Verh Dtsch Ges Pathol. 1996. PMID: 9020569 Review. - [Role of the thymus in the physiopathology of myasthenia].
Eymard B, Berrih-Aknin S. Eymard B, et al. Rev Neurol (Paris). 1995 Jan;151(1):6-15. Rev Neurol (Paris). 1995. PMID: 7676132 Review. French.
Cited by
- Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.
Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifirò G, De Luca A. Crisafulli S, et al. CNS Drugs. 2024 Jan;38(1):15-32. doi: 10.1007/s40263-023-01059-8. Epub 2024 Jan 11. CNS Drugs. 2024. PMID: 38212553 Review. - Anti-cytokine autoantibodies: mechanistic insights and disease associations.
Cheng A, Holland SM. Cheng A, et al. Nat Rev Immunol. 2024 Mar;24(3):161-177. doi: 10.1038/s41577-023-00933-2. Epub 2023 Sep 19. Nat Rev Immunol. 2024. PMID: 37726402 Review. - Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield JI, Aizenbud L, Perdigoto AL, Meffre E, Jilaveanu L, Michalek DA, Rich SS, Aizenbud Y, Adeniran A, Herold KC, Austin MR, Kluger H. Caulfield JI, et al. J Immunother Cancer. 2023 Mar;11(3):e006570. doi: 10.1136/jitc-2022-006570. J Immunother Cancer. 2023. PMID: 36898736 Free PMC article. - Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation.
Ramsaroop T, Gelinas D, Kang SA, Govindarajan R. Ramsaroop T, et al. BMC Neurol. 2023 Jan 12;23(1):12. doi: 10.1186/s12883-022-02922-9. BMC Neurol. 2023. PMID: 36631752 Free PMC article. - Myasthenia Gravis: An Acquired Interferonopathy?
Payet CA, You A, Fayet OM, Dragin N, Berrih-Aknin S, Le Panse R. Payet CA, et al. Cells. 2022 Apr 4;11(7):1218. doi: 10.3390/cells11071218. Cells. 2022. PMID: 35406782 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources